Hamilton Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Hamilton Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-462	Closed	-$217K	–	132
2024 Q2	$217K	Buy	+462	New	+$201K	0.06%	91

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Hamilton Wealth's VRTX Position: Q3 2024 in Review

Hamilton Wealth sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 462 shares — an estimated $217K sold.

Hamilton Wealth first reported a position in VRTX in Q2 2024 and held it in 1 quarter. The position peaked at $217K in Q2 2024. 1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

Hamilton Wealth reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Hamilton Wealth sold 462 Vertex Pharmaceuticals shares in Q3 2024, an estimated $217K.
Hamilton Wealth first reported a position in Vertex Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Hamilton Wealth's Vertex Pharmaceuticals position peaked at $217K in Q2 2024.
1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Hamilton Wealth's 13F filing for Q3 2024, filed 14 Nov 2024.